
Jean-Louis Laplanche

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10723705/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
2	An <i>in vivo Caenorhabditis elegans</i> model for therapeutic research in human prion diseases. Brain, 2021, 144, 2745-2758.	7.6	3
3	Clustering suicidal phenotypes and genetic associations with brain-derived neurotrophic factor in patients with substance use disorders. Translational Psychiatry, 2021, 11, 72.	4.8	4
4	POLR1B and neural crest cell anomalies in Treacher Collins syndrome type 4. Genetics in Medicine, 2020, 22, 547-556.	2.4	63
5	Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research and Therapy, 2020, 12, 123.	6.2	33
6	A novel deep intronic variant in <i>ATP7B</i> in five unrelated families affected by Wilson disease. Molecular Genetics & Genomic Medicine, 2020, 8, e1428.	1.2	8
7	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	10.2	42
8	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
9	Translational study of the whole transcriptome in rats and genetic polymorphisms in humans identifies LRP1B and VPS13A as key genes involved in tolerance to cocaine-induced motor disturbances. Translational Psychiatry, 2020, 10, 381.	4.8	6
10	The neurobehavioral effects of the designer drug naphyrone – an experimental investigation with pharmacokinetics and concentration/effect relationship in mice. Psychopharmacology, 2020, 237, 1943-1957.	3.1	4
11	Title is missing!. , 2020, 17, e1003289.		0
12	Title is missing!. , 2020, 17, e1003289.		0
13	Title is missing!. , 2020, 17, e1003289.		0
14	Title is missing!. , 2020, 17, e1003289.		0
15	Title is missing!. , 2020, 17, e1003289.		0
16	Title is missing!. , 2020, 17, e1003289.		0
17	Title is missing!. , 2020, 17, e1003289.		0
18	QT length during methadone maintenance treatment: geneÂ×Âdose interaction. Fundamental and Clinical Pharmacology, 2019, 33, 96-106.	1.9	10

#	Article	IF	CITATIONS
19	Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. Psychopharmacology, 2019, 236, 891-901.	3.1	5
20	Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology, 2019, 93, e125-e134.	1.1	73
21	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau. PLoS ONE, 2019, 14, e0217026.	2.5	18
22	Autosomal recessive Treacher Collins syndrome due to <i>POLR1C</i> mutations: Report of a new family and review of the literature. American Journal of Medical Genetics, Part A, 2019, 179, 1390-1394.	1.2	19
23	CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 29.	6.2	19
24	Acute and chronic neurobehavioral effects of the designer drug and bath salt constituent 3,4-methylenedioxypyrovalerone in the rat. Journal of Psychopharmacology, 2019, 33, 392-405.	4.0	21
25	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored forÂCognitive Disorders. Journal of Alzheimer's Disease, 2018, 64, 889-897.	2.6	9
26	High genetic carrier frequency of Wilson's disease in France: discrepancies with clinical prevalence. BMC Medical Genetics, 2018, 19, 143.	2.1	47
27	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700.	1.4	5
28	Neurobehavioral effects of lithium in the rat: Investigation of the effect/concentration relationships and the contribution of the poisoning pattern. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 124-133.	4.8	9
29	Region-specific protein misfolding cyclic amplification reproduces brain tropism of prion strains. Journal of Biological Chemistry, 2017, 292, 16688-16696.	3.4	6
30	Accuracy of diagnosis criteria in patients with suspected diagnosis of sporadic Creutzfeldt-Jakob disease and detection of 14-3-3 protein, France, 1992 to 2009. Eurosurveillance, 2017, 22, .	7.0	20
31	Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. Journal of Alzheimer's Disease, 2016, 51, 905-913.	2.6	21
32	Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Science Translational Medicine, 2016, 8, 370ra182.	12.4	114
33	Mechanisms of tramadol-related neurotoxicity in the rat: Does diazepam/tramadol combination play a worsening role in overdose?. Toxicology and Applied Pharmacology, 2016, 310, 108-119.	2.8	40
34	Quantifying prion disease penetrance using large population control cohorts. Science Translational Medicine, 2016, 8, 322ra9.	12.4	289
35	Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts. Epigenomics, 2016, 8, 181-195.	2.1	17
36	Treacher Collins syndrome: a clinical and molecular study based on a large series of patients. Genetics in Medicine, 2016, 18, 49-56.	2.4	125

#	Article	IF	CITATIONS
37	Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic. Molecular Neurobiology, 2016, 53, 2189-2199.	4.0	80
38	A cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadoneâ€maintained outpatients. American Journal on Addictions, 2015, 24, 613-620.	1.4	23
39	Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer's Research and Therapy, 2015, 7, 30.	6.2	101
40	Methadone dose in heroinâ€dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. British Journal of Clinical Pharmacology, 2015, 79, 967-977.	2.4	57
41	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. Journal of Psychiatry and Neuroscience, 2015, 40, 151-161.	2.4	75
42	Genotyping Test with Clinical Factors: Better Management of Acute Postoperative Pain?. International Journal of Molecular Sciences, 2015, 16, 6298-6311.	4.1	12
43	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimer's Research and Therapy, 2014, 6, 38.	6.2	44
44	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
45	Large deletions encompassing the TCOF1 and CAMK2A genes are responsible for Treacher Collins syndrome with intellectual disability. European Journal of Human Genetics, 2014, 22, 52-56.	2.8	22
46	Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 150-158.	10.2	157
47	The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. Journal of Neurology, 2014, 261, 1187-1195.	3.6	11
48	KCNH2 polymorphism and methadone dosage interact to enhance QT duration. Drug and Alcohol Dependence, 2014, 141, 34-38.	3.2	18
49	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiology of Disease, 2013, 54, 486-491.	4.4	14
50	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
51	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimer's and Dementia, 2013, 9, 406-413.	0.8	63
52	Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. Pharmacogenomics, 2013, 14, 575-585.	1.3	37
53	Impact of the 2008–2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. Journal of Alzheimer's Disease, 2013, 34, 297-305.	2.6	51
54	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer's Disease. PLoS ONE, 2013, 8, e53587.	2.5	46

#	Article	IF	CITATIONS
55	Glycoform-Selective Prion Formation in Sporadic and Familial Forms of Prion Disease. PLoS ONE, 2013, 8, e58786.	2.5	32
56	Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain, 2012, 135, 3051-3061.	7.6	135
57	Substitutions at residue 211 in the prion protein drive a switch between CJD and GSS syndrome, a new mechanism governing inherited neurodegenerative disorders. Human Molecular Genetics, 2012, 21, 5417-5428.	2.9	29
58	Genome-wide study links MTMR7 gene to variant Creutzfeldt-Jakob risk. Neurobiology of Aging, 2012, 33, 1487.e21-1487.e28.	3.1	40
59	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. Biological Psychiatry, 2012, 71, 829-835.	1.3	52
60	Epidemiogenetic study of French families with Paget's disease of bone. Joint Bone Spine, 2012, 79, 393-398.	1.6	31
61	Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: The cognitive reserve theory. Neurobiology of Disease, 2010, 40, 456-459.	4.4	30
62	Neuron Dysfunction Is Induced by Prion Protein with an Insertional Mutation via a Fyn Kinase and Reversed by Sirtuin Activation in <i>Caenorhabditis elegans</i> . Journal of Neuroscience, 2010, 30, 5394-5403.	3.6	51
63	Rare E196K mutation in the PRNP gene of a patient exhibiting behavioral abnormalities. Clinical Neurology and Neurosurgery, 2010, 112, 244-247.	1.4	7
64	Variant Creutzfeldt–Jakob disease in France and the United Kingdom: Evidence for the same agent strain. Annals of Neurology, 2009, 65, 249-256.	5.3	67
65	Loss of Cerebellar Granule Neurons Is Associated With Punctate but Not With Large Focal Deposits of Prion Protein in Creutzfeldt-Jakob Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 892-901.	1.7	9
66	Human prion diseases: from antibody screening to a standardized fast immunodiagnosis using automation. Modern Pathology, 2008, 21, 140-149.	5.5	12
67	V180I mutation of the prion protein gene associated with atypical PrPSc glycosylation. Neuroscience Letters, 2006, 408, 165-169.	2.1	43
68	Paget's Disease of Bone in the French Population: Novel SQSTM1 Mutations, Functional Analysis, and Genotype-Phenotype Correlations. Journal of Bone and Mineral Research, 2006, 22, 310-317.	2.8	67
69	Genetics ofÂPaget's disease ofÂbone. Joint Bone Spine, 2006, 73, 243-248.	1.6	45
70	Striking PrPscheterogeneity in inherited prion diseases with the D178N mutation. Annals of Neurology, 2004, 56, 910-911.	5.3	17
71	The Human "Prion-like―Protein Doppel Is Expressed in Both Sertoli Cells and Spermatozoa. Journal of Biological Chemistry, 2002, 277, 43071-43078.	3.4	75
72	Serotonin transporter gene polymorphism influences age at onset in patients with bipolar affective disorder. Neuroscience Letters, 2002, 334, 17-20.	2.1	53

JEAN-LOUIS LAPLANCHE

#	Article	IF	CITATIONS
73	Determination of 14–3–3 protein levels in cerebrospinal fluid from Creutzfeldt–Jakob patients by a highly sensitive capture assay. Neuroscience Letters, 2001, 301, 167-170.	2.1	28
74	Serotonin transporter gene polymorphism and psychiatric disorders in NF1 patients. American Journal of Medical Genetics Part A, 2001, 105, 758-760.	2.4	2
75	Distribution of the M129V polymorphism of the prion protein gene in a Turkish population suggests a high risk for Creutzfeldt-Jakob disease. European Journal of Human Genetics, 2001, 9, 965-968.	2.8	31
76	Identification of three novel mutations (E196K, V203I, E211Q) in the prion protein gene (PRNP) in in in inherited prion diseases with Creutzfeldt-Jakob disease phenotype. Human Mutation, 2000, 15, 482-482.	2.5	87
77	PrP immunohistochemistry: Different protocols, including a procedure for long formalin fixation, and a proposed schematic classification for deposits in sporadic Creutzfeldt-Jakob disease. Microscopy Research and Technique, 2000, 50, 26-31.	2.2	23
78	Novel approaches in diagnosis and therapy of Creutzfeldt–Jakob disease. Mechanisms of Ageing and Development, 2000, 116, 193-218.	4.6	41
79	First report of polymorphisms in the prion-like protein gene (PRND): implications for human prion diseases. Neuroscience Letters, 2000, 286, 144-148.	2.1	73
80	Possible association between serotonin transporter gene polymorphism and violent suicidal behavior in mood disorders. Biological Psychiatry, 2000, 48, 319-322.	1.3	143
81	Prominent psychiatric features and early onset in an inherited prion disease with a new insertional mutation in the prion protein gene. Brain, 1999, 122, 2375-2386.	7.6	83
82	Mutation at codon 210 (V210I) of the prion protein gene in a North African patient with Creutzfeldt-Jakob disease. Journal of the Neurological Sciences, 1999, 168, 141-144.	0.6	23
83	Cluster of Creutzfeldt-Jakob disease in France associated with the codon 200 mutation (E200K) in the prion protein gene. European Journal of Neurology, 1998, 5, 375-379.	3.3	10
84	Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression. Neuroscience Letters, 1998, 255, 143-146.	2.1	123
85	Serotonin transporter gene and manic depressive illness: An association study. Biological Psychiatry, 1997, 41, 750-752.	1.3	59
86	Deletions in the prion protein gene are not associated with CJD. Human Molecular Genetics, 1993, 2, 541-544.	2.9	97
87	Deletion in prion protein gene in a Moroccan family. Nucleic Acids Research, 1990, 18, 6745-6745.	14.5	55